{
    "eid": "2-s2.0-84925408172",
    "title": "Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: Final event-driven analysis of the randomized, double-blind PATRICIA trial",
    "cover-date": "2015-04-01",
    "subject-areas": [
        {
            "$": "Immunology and Allergy",
            "@code": "2723"
        },
        {
            "$": "Immunology",
            "@code": "2403"
        },
        {
            "$": "Clinical Biochemistry",
            "@code": "1308"
        },
        {
            "$": "Microbiology (medical)",
            "@code": "2726"
        }
    ],
    "keywords": [],
    "authors": [
        "Dan Apter"
    ],
    "citedby-count": 79,
    "ref-count": 44,
    "ref-list": [
        "GLOBOCAN v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11",
        "The causal relation between human papillomavirus and cervical cancer",
        "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study",
        "Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials",
        "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines",
        "Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant",
        "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial",
        "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women",
        "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial",
        "Sustained efficacy up to 4\u00b75 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial",
        "Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6\u00b74 years",
        "Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women",
        "HPV infections in adolescents",
        "Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008",
        "Introducing HPV vaccine in developing countries - Key challenges and issues",
        "Age considerations when vaccinating against HPV",
        "The Australian experience with the human papillomavirus vaccine",
        "Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: Guarding against guessing",
        "Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR",
        "Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine",
        "Guidelines and Resources",
        "Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women",
        "Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial",
        "Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases",
        "Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions",
        "Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials",
        "Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial",
        "HPV testing in routine cervical screening: Cross sectional data from the ARTISTIC trial",
        "HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN",
        "Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark",
        "Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observation",
        "Clinical trials of human papillomavirus vaccines and beyond",
        "Strategies for the introduction of human papillomavirus vaccination: Modelling the optimum age- and sex-specific pattern of vaccination in Finland",
        "Health and economic implications of HPV vaccination in the United States",
        "The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women",
        "A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16",
        null,
        "Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types",
        "Introduction of HPV Vaccines in EU Countries - An Update",
        "Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014 \u2014 United States",
        "Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses",
        "Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan"
    ],
    "affiliation": [
        {
            "affiliation-city": "Manchester",
            "affilname": "Health Innovation Manchester",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Wavre",
            "affilname": "GlaxoSmithKline Pharmaceuticals SA/NV",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Philadelphia",
            "affilname": "GlaxoSmithKline, USA",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Congella",
            "affilname": "Centre for the AIDS Programme of Research in South Africa",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "Manila",
            "affilname": "University of the Philippines College of Medicine",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Jette",
            "affilname": "Universitair Ziekenhuis Brussel",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Wurzburg",
            "affilname": "Universit\u00e4tsklinikum W\u00fcrzburg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Leuven",
            "affilname": "KU Leuven\u2013 University Hospital Leuven",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Edmonton",
            "affilname": "University of Alberta",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Campinas",
            "affilname": "Universidade Estadual de Campinas",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Melbourne",
            "affilname": "University of Melbourne",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Sydney",
            "affilname": "The University of Sydney",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University College of Medicine",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Albuquerque",
            "affilname": "UNM Health Sciences Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Tampere",
            "affilname": "Tampere School of Public Health",
            "affiliation-country": "Finland"
        },
        {
            "affiliation-city": "London",
            "affilname": "Barts and The London School of Medicine and Dentistry",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Helsinki",
            "affilname": "Vaestoliitto",
            "affiliation-country": "Finland"
        },
        {
            "affiliation-city": "Porto Alegre",
            "affilname": "Hospital de Clinicas de Porto Alegre",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital Universitari de Bellvitge",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Winnipeg",
            "affilname": "University of Manitoba",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Mexico",
            "affilname": "Instituto Mexicano del Seguro Social",
            "affiliation-country": "Mexico"
        },
        {
            "affiliation-city": "Helsinki",
            "affilname": "Helsingin Yliopisto",
            "affiliation-country": "Finland"
        },
        {
            "affiliation-city": "Perth",
            "affilname": "The Kids Research Institute Australia",
            "affiliation-country": "Australia"
        }
    ],
    "funding": []
}